Drug intelligence / Profile preview

1612

Development stage: Phase 4
Modality: Small Molecules
Administration: Oral

Overview

1612 is an investigational drug administered in capsule form. It was being evaluated in a clinical trial for its efficacy and safety in patients with amnestic mild cognitive impairment. The study, which was a multicenter, randomized, double-blind, placebo-controlled, parallel trial, aimed to assess changes in cognitive scales and conversion rates to dementia. The clinical trial for this drug was subsequently withdrawn.

Other names: 1612 capsules

Beyond the preview

Go deeper on 1612.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1612.

Explore the full profile